CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤 Idecabtagene-Vicleucel 治疗后免疫效应细胞相关血液毒性伴继发性骨髓纤维化，经自体造血干细胞支持综合治疗
英文原题：Immune Effector Cell-Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene-Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting.
查看英文原题
Immune Effector Cell-Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene-Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
伴随CAR-T 细胞治疗发生的全血细胞减少称为免疫效应细胞相关造血毒性（ICAHT），通常持续存在且对支持治疗难治。我们报告一例52岁多发性骨髓瘤男性患者，在接受idecabtagene vicleucel后发生严重ICAHT并继发骨髓纤维化（sMF），经自体造血干细胞补充治疗后得到全面改善。本病例聚焦sMF这一罕见但需警惕的CAR-T 治疗并发症，强调进行骨髓活检以排除sMF的重要性，以及采用干细胞补充治疗持续性ICAHT的价值。
展开英文摘要原文
Pancytopenia accompanied by chimeric antigen receptor T cell (CAR-T) therapy is termed immune effector cell-associated hematopoietic toxicity (ICAHT), which is often sustained and refractory to supportive care.
We report a case of a 52-year-old man with multiple myeloma who developed severe ICAHT with secondary myelofibrosis (sMF) after administration of idecabtagene-vicleucel, which was comprehensively improved by autologous hematopoietic stem cell boosting. This case focuses on sMF as a rare but cautionary complication of CAR-T therapy, underscoring the importance of bone marrow biopsy to exclude sMF and of stem cell boosting for the treatment of persistent ICAHT.
论文信息
- 作者
- Ogura K、Fujino T、Nakamura T、Miyashita A、Onishi A、Tsukamoto T、Mizutani S、Shimura Y
- 单位
- Division of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan.Japan
- 期刊
- EJHaem2026 Aug
- 原文标识
- PubMed 42415719 · DOI 10.1002/jha2.70348
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →